288 related articles for article (PubMed ID: 22577855)
1. The anti-tumor performance of docetaxel liposomes surface-modified with glycyrrhetinic acid.
Li J; Xu H; Ke X; Tian J
J Drug Target; 2012 Jun; 20(5):467-73. PubMed ID: 22577855
[TBL] [Abstract][Full Text] [Related]
2. A wogonin-loaded glycyrrhetinic acid-modified liposome for hepatic targeting with anti-tumor effects.
Tian J; Wang L; Wang L; Ke X
Drug Deliv; 2014 Nov; 21(7):553-9. PubMed ID: 24215357
[TBL] [Abstract][Full Text] [Related]
3. Transporter occluded-state conformation-induced endocytosis: Amino acid transporter ATB
Luo Q; Gong P; Sun M; Kou L; Ganapathy V; Jing Y; He Z; Sun J
J Control Release; 2016 Dec; 243():370-380. PubMed ID: 27810556
[TBL] [Abstract][Full Text] [Related]
4. Glycyrrhetinic acid-graft-hyaluronic acid conjugate as a carrier for synergistic targeted delivery of antitumor drugs.
Zhang L; Yao J; Zhou J; Wang T; Zhang Q
Int J Pharm; 2013 Jan; 441(1-2):654-64. PubMed ID: 23117024
[TBL] [Abstract][Full Text] [Related]
5. Hepatocellular Carcinoma Targeting and Pharmacodynamics of Paclitaxel Nanoliposomes Modified by Glycyrrhetinic Acid and Ferric Tetroxide.
Zhao L; Liang L; Guo M; Li M; Yu X; Wang Y; Wang Y
Curr Top Med Chem; 2021 Oct; 21(14):1268-1284. PubMed ID: 34620053
[TBL] [Abstract][Full Text] [Related]
6. Development of 11-DGA-3-
Zhou L; Zou M; Zhu K; Ning S; Xia X
Molecules; 2019 Aug; 24(17):. PubMed ID: 31450608
[TBL] [Abstract][Full Text] [Related]
7. Cellular uptake mechanism and clearance kinetics of fluorescence-labeled glycyrrhetinic acid and glycyrrhetinic acid-modified liposome in hepatocellular carcinoma cells.
Sun Y; Lu J; Yan D; Shen L; Hu H; Chen D
Environ Toxicol Pharmacol; 2017 Jul; 53():46-56. PubMed ID: 28501784
[TBL] [Abstract][Full Text] [Related]
8. Doxorubicin-loaded glycyrrhetinic acid modified recombinant human serum albumin nanoparticles for targeting liver tumor chemotherapy.
Qi WW; Yu HY; Guo H; Lou J; Wang ZM; Liu P; Sapin-Minet A; Maincent P; Hong XC; Hu XM; Xiao YL
Mol Pharm; 2015 Mar; 12(3):675-83. PubMed ID: 25584860
[TBL] [Abstract][Full Text] [Related]
9. Hepatocellular carcinoma-targeted effect of configurations and groups of glycyrrhetinic acid by evaluation of its derivative-modified liposomes.
Sun Y; Dai C; Yin M; Lu J; Hu H; Chen D
Int J Nanomedicine; 2018; 13():1621-1632. PubMed ID: 29588589
[TBL] [Abstract][Full Text] [Related]
10. Glycyrrhetinic Acid and TAT Peptide Modified Dual-functional Liposomes for Treatment of Hepatocellular Cancer.
Huang S; Ren D; Wu X; Li M; Yu X; Nie X; Wang Y; Wang Y
Curr Top Med Chem; 2020; 20(27):2493-2505. PubMed ID: 32703132
[TBL] [Abstract][Full Text] [Related]
11. Glycyrrhetinic Acid-Mediated Polymeric Drug Delivery Targeting the Acidic Microenvironment of Hepatocellular Carcinoma.
Zhang J; Zhang M; Ji J; Fang X; Pan X; Wang Y; Wu C; Chen M
Pharm Res; 2015 Oct; 32(10):3376-90. PubMed ID: 26148773
[TBL] [Abstract][Full Text] [Related]
12. Glycyrrhetinic Acid Mediated Drug Delivery Carriers for Hepatocellular Carcinoma Therapy.
Cai Y; Xu Y; Chan HF; Fang X; He C; Chen M
Mol Pharm; 2016 Mar; 13(3):699-709. PubMed ID: 26808002
[TBL] [Abstract][Full Text] [Related]
13. Solid dispersion and effervescent techniques used to prepare docetaxel liposomes for lung-targeted delivery system: in vitro and in vivo evaluation.
Zhao L; Wei Y; Li W; Liu Y; Wang Y; Zhong X; Yu Y
J Drug Target; 2011 Apr; 19(3):171-8. PubMed ID: 20429774
[TBL] [Abstract][Full Text] [Related]
14. A pH-responsive α-helical cell penetrating peptide-mediated liposomal delivery system.
Zhang Q; Tang J; Fu L; Ran R; Liu Y; Yuan M; He Q
Biomaterials; 2013 Oct; 34(32):7980-93. PubMed ID: 23891517
[TBL] [Abstract][Full Text] [Related]
15. Preparation, characterization and uptake by primary cultured rat hepatocytes of liposomes surface-modified with glycyrrhetinic acid.
Mao SJ; Bi YQ; Jin H; Wei DP; He R; Hou SX
Pharmazie; 2007 Aug; 62(8):614-9. PubMed ID: 17867558
[TBL] [Abstract][Full Text] [Related]
16. A novel glycyrrhetinic acid-modified oxaliplatin liposome for liver-targeting and in vitro/vivo evaluation.
Chen J; Jiang H; Wu Y; Li Y; Gao Y
Drug Des Devel Ther; 2015; 9():2265-75. PubMed ID: 25945038
[TBL] [Abstract][Full Text] [Related]
17. RGD-modified pH-sensitive liposomes for docetaxel tumor targeting.
Chang M; Lu S; Zhang F; Zuo T; Guan Y; Wei T; Shao W; Lin G
Colloids Surf B Biointerfaces; 2015 May; 129():175-82. PubMed ID: 25851582
[TBL] [Abstract][Full Text] [Related]
18. Dual-Ligand-Functionalized Liposomes Based on Glycyrrhetinic Acid and cRGD for Hepatocellular Carcinoma Targeting and Therapy.
Qiu M; Wang J; Bai J; Li X; Tian C; Liu Z; Zheng C; Clark AR; Cheng X; Liao X; Wu S; Lee RJ; Zhou X
Mol Pharm; 2023 Apr; 20(4):1951-1963. PubMed ID: 36952242
[TBL] [Abstract][Full Text] [Related]
19. Glycyrrhetinic acid-modified poly(ethylene glycol)-b-poly(gamma-benzyl l-glutamate) micelles for liver targeting therapy.
Huang W; Wang W; Wang P; Tian Q; Zhang C; Wang C; Yuan Z; Liu M; Wan H; Tang H
Acta Biomater; 2010 Oct; 6(10):3927-35. PubMed ID: 20438873
[TBL] [Abstract][Full Text] [Related]
20. The anti-tumoral efficacy of a docetaxel-loaded liposomal drug delivery system modified with transferrin for ovarian cancer.
Yuan MQ; Zhu F; Lou JY; Yuan WM; Fu L; Liu S; Zhang ZZ; Liu CY; He Q
Drug Res (Stuttg); 2014 Apr; 64(4):195-202. PubMed ID: 24154938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
